Higher Levels of Immunoglobulin E and Thymus and Activation-Regulated Chemokine Are Associated with Conjunctivitis During Lebrikizumab Treatment in Patients with Moderate-to-Severe Atopic Dermatitis
Dermatitis® · 2025
DOI: 10.1089/derm.2025.0121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatitis®, 2025. Verfasst von Teppei Hagino und 3 weiteren Autor:innen. Beteiligte Einrichtung: From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Immunoglobulin E, Chemokine CCL17, Conjunctivitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Fujimoto Dermatology Clinic, Funabashi, Japan.
ORCID-Profile: Teppei Hagino
Zitieren
APA
Hagino, T., Saeki, H., Fujimoto, E., & Kanda, N. (2025). Higher Levels of Immunoglobulin E and Thymus and Activation-Regulated Chemokine Are Associated with Conjunctivitis During Lebrikizumab Treatment in Patients with Moderate-to-Severe Atopic Dermatitis. Dermatitis®. https://doi.org/10.1089/derm.2025.0121
Vancouver
Hagino T, Saeki H, Fujimoto E, Kanda N. Higher Levels of Immunoglobulin E and Thymus and Activation-Regulated Chemokine Are Associated with Conjunctivitis During Lebrikizumab Treatment in Patients with Moderate-to-Severe Atopic Dermatitis. Dermatitis®. 2025. doi:10.1089/derm.2025.0121
BibTeX
@article{Hagino2025,
author = {Hagino, Teppei and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
title = {Higher Levels of Immunoglobulin E and Thymus and Activation-Regulated Chemokine Are Associated with Conjunctivitis During Lebrikizumab Treatment in Patients with Moderate-to-Severe Atopic Dermatitis},
journal = {Dermatitis®},
year = {2025},
doi = {10.1089/derm.2025.0121}
}
EUVIMED